Arrowhead Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Cash & Equivalents	201.64	224.65	99.19	102.99	100.71	184.43
Short-Term Investments	714.97	692.82	578.28	292.74	268.39	183.36
Cash & Short-Term Investments	916.61	917.47	677.46	395.73	369.1	367.79
Cash Growth	66.40%	35.43%	71.19%	7.22%	0.36%	16.58%
Receivables	218.87	6.82	-	-	1.41	10.26
Prepaid Expenses	16.05	10.93	9.54	8.81	7.29	4.36
Restricted Cash	-	1.9	3.5	7.9	7.3	-
Other Current Assets	22.86	13.52	4.97	4.03	20.2	2.19
Total Current Assets	1,174	950.64	695.47	416.47	405.3	384.6
Property, Plant & Equipment	421.95	426.41	431.29	335.56	168.59	66.02
Long-Term Investments	-	-	-	-	105.87	245.6
Other Intangible Assets	6.44	6.86	8.56	10.26	11.96	13.66
Other Long-Term Assets	1.41	1.39	4.48	3.26	0.22	0.27
Total Assets	1,604	1,385	1,140	765.55	691.94	710.15
Accounts Payable	32.94	17.67	11.39	35.87	2.87	9.46
Accrued Expenses	144.35	96.24	80.8	43.68	59.11	23.77
Short-Term Debt	-	10.3	-	-	-	-
Current Portion of Long-Term Debt	40	40	-	-	-	-
Current Portion of Leases	7.53	7.29	6.34	10.56	2.78	2.25
Current Income Taxes Payable	-	20.8	-	-	-	-
Current Unearned Revenue	111.93	2.4	-	0.87	74.1	111.06
Other Current Liabilities	10.68	0.79	4.64	14.48	-	-
Total Current Liabilities	347.43	195.49	103.17	105.46	138.85	146.54
Long-Term Debt	538.11	582.28	734.54	268.33	-	-
Long-Term Leases	102.13	104.11	111.03	104.61	78.8	23.3
Long-Term Unearned Revenue	53.83	-	-	-	55.95	131.5
Total Liabilities	1,041	881.88	948.74	478.39	273.6	301.33
Common Stock	0.23	0.23	0.22	0.2	0.2	0.2
Additional Paid-In Capital	2,211	2,140	1,806	1,300	1,219	1,053
Retained Earnings	-1,596	-1,627	-1,626	-1,026	-820.76	-644.69
Treasury Stock	-53.19	-53.19	-	-	-	-
Comprehensive Income & Other	6.7	6.44	4.75	-3.22	-0.14	-0.07
Total Common Equity	568.42	466.05	185.44	271.34	398.52	408.82
Minority Interest	-5.73	37.36	5.62	15.82	19.82	-
Shareholders' Equity	562.7	503.42	191.06	287.16	418.34	408.82
Total Liabilities & Equity	1,604	1,385	1,140	765.55	691.94	710.15
Total Debt	687.76	743.98	851.91	383.5	81.58	25.55
Net Cash (Debt)	228.85	173.49	-174.45	12.23	287.52	342.24
Net Cash Growth	-	-	-	-95.75%	-15.99%	16.27%
Net Cash Per Share	1.66	1.30	-1.46	0.11	2.73	3.30
Filing Date Shares Outstanding	140.03	135.81	124.43	107.43	106.01	104.53
Total Common Shares Outstanding	137.39	135.7	124.38	107.31	105.96	104.33
Working Capital	826.96	755.15	592.3	311.02	266.45	238.06
Book Value Per Share	4.14	3.43	1.49	2.53	3.76	3.92
Tangible Book Value	561.99	459.19	176.88	261.08	386.56	395.16
Tangible Book Value Per Share	4.09	3.38	1.42	2.43	3.65	3.79
Land	-	3	3	3	3	-
Buildings	-	251.32	75.99	-	-	-
Machinery	-	88	71.93	58.75	40.47	29.67
Construction In Progress	-	15.94	188.73	166.66	56.37	0.35
Leasehold Improvements	-	104.43	104.41	103.81	42.02	41.52

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.